QLC5508 is named as a drug or biological intervention in 4 clinical trials in our China trial register, 4 of which are recruiting. The lead sponsor is Qilu Pharmaceutical Co., Ltd.. Registered phases: Phase 1/2, Phase 1 and Phase 3. Conditions studied include Refractory or Relapsed Solid Tumors; Esophageal Squamous Cell Carcinoma (ESCC); Advanced Solid Tumor.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07463573 | QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ClinicalTrials.gov ↗) Esophageal Squamous Cell Carcinoma (ESCC) |
Phase 3 | Recruiting |
| NCT07198633 | A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer (ClinicalTrials.gov ↗) Advanced Prostate Cancer |
Phase 1/2 | Recruiting |
| NCT07256782 | A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumor |
Phase 1/2 | Recruiting |
| NCT07620041 | Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction (ClinicalTrials.gov ↗) Refractory or Relapsed Solid Tumors |
Phase 1 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Refractory or Relapsed Solid Tumors | 1 |
| Esophageal Squamous Cell Carcinoma (ESCC) | 1 |
| Advanced Solid Tumor | 1 |
| Advanced Prostate Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Qilu Pharmaceutical Co., Ltd. | 4 |
| Register | QLC5508 trials |
|---|---|
| Clinical trials in China | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how QLC5508 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists QLC5508 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.